XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Total revenue $ 173.1 $ 164.0
Costs and expenses:    
Research and development expense 23.1 19.7
Change in the fair value of contingent consideration 0.9 (3.4)
Selling, general, and administrative expense 145.5 132.9
Goodwill and intangible asset impairment charges 0.0 98.4
Total costs and expenses 219.8 297.7
Operating loss (46.7) (133.7)
Other income (expense):    
Interest income 0.2 0.8
Interest expense (3.0) (2.3)
Other (0.1) 4.1
Total other income (expense), net (2.9) 2.6
Loss before income tax (49.6) (131.1)
Income tax benefit (10.1) (15.9)
Net loss (39.5) (115.2)
Net loss attributable to non-controlling interest 0.0 0.0
Net loss attributable to Myriad Genetics, Inc. stockholders $ (39.5) $ (115.2)
Net loss per share:    
Basic (in dollars per share) $ (0.52) $ (1.55)
Diluted (in dollars per share) $ (0.52) $ (1.55)
Weighted average shares outstanding:    
Basic (shares) 76.0 74.5
Diluted (shares) 76.0 74.5
Molecular diagnostic testing    
Total revenue $ 159.6 $ 150.5
Costs and expenses:    
Costs and expenses 44.1 43.1
Pharmaceutical and clinical services    
Total revenue 13.5 13.5
Costs and expenses:    
Costs and expenses $ 6.2 $ 7.0